

PATENT
ATTORNEY'S DOCKET NUMBER GM50057

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE
(DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED
PCT/US00/12133 04 May 2000 20 May 1999

TITLE OF INVENTION

Methods of Modulating Activity of Prokaryotic Ribosomes

APPLICANT(S) FOR DO/US

Donna M. FERGUSON, Lisa Anne HEGG, Kelvin C. NURSE, and Therese Anne STERNER

Box PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

ATTENTION: DO/US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date 13 November 2001 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EL 808 220 843 US** addressed to the:

Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan L. Johnson
(Typed or printed name of person mailing paper)

Susan L. Johnson
(Signature of person mailing paper)



20462

Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NUMBER GM50057
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/019369
INTERNATIONAL APPLICATION NO. PCT/US00/12133	INTERNATIONAL FILING DATE 04 May 2000	PRIORITY DATE CLAIMED 20 May 2000
TITLE OF INVENTION Methods of Modulating Activity of Prokaryotic Ribosomes		
APPLICANT(S) FOR DO/EO/US Donna M. FERGUSON, Lisa Anne HEGG, Kelvin C. NURSE, and Therese Anne STERNER		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.
12. An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
14. A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/US00/12133, filed 04 May 2000, which claims benefit from the following Provisional Application: 60/134,973, filed 20 May 1999, 60/137,837
16. A substitute specification.
17. A change of power of attorney and/or address letter.
18. An Abstract on a separate sheet of paper.
19. Other items or information: Sequence Listing in Computer-Readable Format;
Paper Copy of Sequence Listing; Statement to Support.

20. [X] The following fees are submitted:

Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$890.00

International Preliminary Examination Fee paid to USPTO (37 CFR 1.492)
..... \$710.00No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492)
but international search fee paid to USPTO (37 CFR 1.445(a)(2))
..... \$740.00Neither International Preliminary Examination Fee (37 CFR 1.492) nor
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and
all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00**ENTER APPROPRIATE BASIC FEE AMOUNT =****\$710.00**Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).**\$0.00**

Claims Number Filed Number Extra Rate

Total claims 15 - 20 = 0 0 x \$18.00 \$0.00

Independent claims 7 - 3 = 0 4 x \$84.00 \$252.00

Multiple dependent claims (if applicable) + \$280.00 \$0.00

TOTAL OF ABOVE CALCULATIONS =**\$962.00**

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).

SUBTOTAL =**\$962.00**Processing fee of \$130.00 for furnishing the English translation later than
 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +**\$****TOTAL NATIONAL FEE =****\$962.00**Amount to be
refunded \$
charged \$

- a. A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. 19-2570 in the amount of **\$962.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-4478

Facsimile (610) 270-5090



SIGNATURE

Edward R. Gimmi

NAME

38,891

REGISTRATION NO.